The efficacy of neoadjuvant chemotherapy is different for type 4 and large type 3 gastric cancer

Abstract

BackgroundIn the JCOG0501 study, neoadjuvant chemotherapy (NAC) failed to demonstrate survival benefits for type 4 and large type 3 gastric cancer (GC). The prognosis of these patients is still poor. We conducted this study to explore the value of NAC with non-SP regimens for type 4 and large type 3 ​GC in the Chinese population. MethodsWe retrospectively collected data from our electronic medical record system. Patients with large type 3 or type 4 ​GC who underwent D2 gastrectomy and AC were included. Patients were divided into two groups based on whether they received NAC: the CSC (NAC ​+ ​surgery ​+ ​AC) and SC (surgery ​+ ​AC) groups. The survival and perioperative outcomes for large type 3 or type 4 ​GC were analyzed between the CSC and SC groups, separately. ResultsBetween May 2009 and December 2018, 189 patients were reviewed. Among large type 3 ​GC, the 5-year overall survival (OS) rates for patients in the CSC and SC groups were 54.4 ​% and 28.0 ​%, respectively (P ​= ​0.0008). Among type 4 ​GC, the 5-year OS rates for patients in the CSC and SC groups were 15.8 ​% and 24.8 ​%, respectively (P ​> ​0.05). ConclusionsThis study showed NAC can improve the prognosis of large type 3 ​GC. However, NAC did not demonstrate significant survival advantages for type 4 ​GC.